Using the FRAX tool to categorize postmenopausal women and older men into tertiles according to their fracture risk, Ananyeva et al found that a higher proportion of women fell into the high (42.7%) or moderate (46.4%) than low (10.9%) risk groups.

The risk for hip fracture is higher during a treatment break from risedronate than it is during a break from alendronate, study findings indicate.

In patients with rheumatoid arthritis, low-dose glucocorticoids are associated with an increased risk for vertebral fracture, but not with overall or non-vertebral fractures, show findings from a UK-based retrospective cohort study.

Delaying denosumab injections by more than 16 weeks is associated with an increased risk for vertebral fracture among patients with osteoporosis, study findings indicate.

Delaying denosumab injections by more than 16 weeks is associated with an increased risk for vertebral fracture among patients with osteoporosis, study findings indicate.

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

medwireNews : The monoclonal antibody romosozumab has been approved in the USA for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Patients initiating denosumab have a similar 3-year fracture risk to those initiating alendronate, regardless of sex, age, or fracture history, show results of a large study among Danish patients in routine clinical practice.

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.

The aim of this review is to provide healthcare professionals with evidence-based physical activity recommendations, and tips for implementing them in practice  [read more] . Ponzano M, Rodrigues IB, Giangregorio LM. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0103-5

The proportion of patients initiating osteoporosis medication following hip fracture has declined in recent years, despite treatment reducing subsequent fracture risk, analysis of a US medical claims database suggests.

Patients with rheumatoid arthritis who have high cumulative disease activity and functional disability have an elevated 10-year risk for osteoporotic fracture, researchers report.